Reviewing Harpoon Therapeutics Inc. (HARP)’s and Athenex Inc. (NASDAQ:ATNX)’s results

This is therefore a contrasting of the risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership in Harpoon Therapeutics Inc. (NASDAQ:HARP) and Athenex Inc. (NASDAQ:ATNX). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Harpoon Therapeutics Inc. 4.75M 60.70 27.37M -0.94 0.00
Athenex Inc. 89.10M 8.93 117.44M -1.29 0.00

Demonstrates Harpoon Therapeutics Inc. and Athenex Inc. earnings per share, top-line revenue and valuation.


Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Harpoon Therapeutics Inc. -576.21% 0% 0%
Athenex Inc. -131.81% -89.2% -62.5%


The Current Ratio and a Quick Ratio of Harpoon Therapeutics Inc. are 3.8 and 3.8. Competitively, Athenex Inc. has 4.5 and 3.9 for Current and Quick Ratio. Athenex Inc.’s better ability to pay short and long-term obligations than Harpoon Therapeutics Inc.

Analyst Recommendations

The following table given below contains the ratings and recommendations for Harpoon Therapeutics Inc. and Athenex Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Harpoon Therapeutics Inc. 0 0 2 3.00
Athenex Inc. 0 0 0 0.00

Harpoon Therapeutics Inc. has a 94.86% upside potential and an average price target of $23.5.

Insider and Institutional Ownership

Harpoon Therapeutics Inc. and Athenex Inc. has shares owned by institutional investors as follows: 35.2% and 32.2%. Harpoon Therapeutics Inc.’s share owned by insiders are 0.5%. Competitively, insiders own roughly 5.3% of Athenex Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Harpoon Therapeutics Inc. 18.45% 0% 0% 0% 0% 26%
Athenex Inc. -1.07% 10.55% -2.77% -20.99% -17.16% 2.36%

For the past year Harpoon Therapeutics Inc. has stronger performance than Athenex Inc.


Harpoon Therapeutics Inc. beats Athenex Inc. on 7 of the 11 factors.

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer. Its Orascovery product candidates include Oraxol, an oral dosage form, which is in a Phase III trial in metastatic breast cancer for the treatment of advanced gastric cancer; Oratecan, an anticancer agent that is in a Phase 1 study for the treatment of colorectal, lung, ovarian, cervical, pancreatic, upper gastrointestinal, and brain cancer; Oradoxel, an anticancer agent, which is in a Phase 1 clinical study in the treatment of breast, prostate, gastric, head and neck, and lung cancer; and Oratopo, an anticancer for the treatment of cervical, ovarian ,and lung cancer. The company also develops KX-01, a compound, which is in Phase 3 study for the treatment of for actinic keratosis; and KX-02 for the treatment of gliomas. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is based in Buffalo, New York.